Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats.

BACKGROUND Chronic inhibition of endothelial nitric oxide (NO) synthesis by the administration of N(omega)-nitro-L-arginine methyl ester (L-NAME) to rats induces early vascular inflammatory changes [monocyte infiltration into coronary vessels, nuclear factor-kappaB (NF-kappaB) activation, and monocyte chemoattractant protein-1 expression] as well as subsequent arteriosclerosis (medial thickening and perivascular fibrosis) and cardiac fibrosis. However, no direct evidence for the importance of NF-kappaB in this process is known. METHODS AND RESULTS We examined the effect of a cis element decoy strategy to address the functional importance of NF-kappaB in the pathogenesis of cardiovascular remodeling. We found here that in vivo transfection of cis element decoy oligodeoxynucleotides against NF-kappaB to hearts prevented the L-NAME-induced early inflammation and subsequent coronary vascular medial thickening. In contrast, NF-kappaB decoy oligodeoxynucleotide transfection did not decrease the development of fibrosis, the expression of transforming growth factor-beta(1) mRNA, or systolic pressure overload induced by L-NAME administration. CONCLUSIONS The NF-kappaB system participates importantly in the development of early vascular inflammation and subsequent medial thickening but not in fibrogenesis in this model. The present study may provide a new aspect of how endothelium-derived NO contributes to anti-inflammatory and/or antiarteriosclerotic properties of the vascular endothelium in vivo.

[1]  A. Takeshita,et al.  Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. , 2000, Circulation.

[2]  A. Takeshita,et al.  Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. , 1999, Hypertension.

[3]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[4]  A. Takeshita,et al.  Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. , 1998, Circulation research.

[5]  A. Takeshita,et al.  Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[6]  A. Takeshita,et al.  Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. , 1998, Hypertension.

[7]  T. Ogihara,et al.  Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. , 1998, Circulation research.

[8]  R. Virmani,et al.  Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. , 1998, The Journal of clinical investigation.

[9]  R. D. Rudic,et al.  Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. , 1998, The Journal of clinical investigation.

[10]  K. Weber,et al.  Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. , 1997, Circulation.

[11]  A. Takeshita,et al.  Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. , 1997, Hypertension.

[12]  D. Harrison,et al.  Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.

[13]  P. Tsao,et al.  Nitric oxide regulates monocyte chemotactic protein-1. , 1997, Circulation.

[14]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[15]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[16]  A. Takeshita,et al.  Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. , 1997, The Journal of clinical investigation.

[17]  M. Reale,et al.  Monocyte chemotactic protein 1 (MCP-1) is a mitogen for cultured rat vascular smooth muscle cells. , 1997, Journal of vascular research.

[18]  R. Alexander,et al.  Endothelial control of the cardiovascular system: recent advances , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  A. Takeshita,et al.  Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. , 1995, Hypertension.

[20]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[21]  T. Maniatis,et al.  Transcriptional regulation of endothelial cell adhesion molecules : NF-icB and cytokine-inducible enhancers , 2004 .

[22]  P. Libby,et al.  Induction and Stabilization of IκBα by Nitric Oxide Mediates Inhibition of NF-κB (*) , 1995, The Journal of Biological Chemistry.

[23]  R. Busse,et al.  Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. , 1995, Circulation research.

[24]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Von der Leyen Gene therapy inhibiting neointimal vascular lesion , 1995 .

[26]  P. Libby,et al.  Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. , 1995, The Journal of biological chemistry.

[27]  L. Feng,et al.  Kinetics of macrophage subpopulations and expression of monocyte chemoattractant protein‐1 (MCP‐1) in bleomycin‐induced lung injury of rats studied by a novel monoclonal antibody against rat MCP‐1 , 1994, Journal of leukocyte biology.

[28]  S. Ohno,et al.  NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. , 1994, Journal of immunology.

[29]  R. Alexander,et al.  Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. , 1993, The Journal of clinical investigation.

[30]  Yun Xing,et al.  Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate ( , 1993, The Journal of clinical investigation.

[31]  T. Collins Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[32]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.